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ABSTRACT
Propionibacterium acnes strains are recovered from infections linked to surgical procedures, foreign
bodies and septicaemia. This study investigated the antibiotic susceptibility patterns of P. acnes isolates
from different systemic infections and determined the genomic diversity among resistant P. acnes
isolates with low-frequency restriction analysis of chromosomal DNA by pulsed-ﬁeld gel electrophor-
esis (PFGE). In total, 304 P. acnes isolates from 13 laboratories in 13 European countries were tested
against six antimicrobial agents by the NCCLS reference agar dilution method and the breakpoints
recommended by the European Committee on Antimicrobial Susceptibility Testing. Blood isolates were
encountered most frequently, followed by those from skin and soft tissue infections, and abdominal
infections. Of the isolates examined, 2.6% were resistant to tetracycline, 15.1% to clindamycin, and
17.1% to erythromycin. No resistance was observed to linezolid, benzylpenicillin or vancomycin. There
was considerable variation between countries in the proportion of resistant strains, ranging from 83% in
Croatia and 60% in Italy to 0% in The Netherlands. Isolates from blood were predominant among the
resistant isolates. Seventeen clones and 78 banding patterns were identiﬁed among the resistant isolates.
It was concluded that antimicrobial resistance has now emerged among P. acnes isolates from systemic
infections.
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INTRODUCTION
Propionibacterium acnes is a Gram-positive anaer-
obic bacilluswhich is amemberof the residentﬂora
of the skin, nares, conjunctival ﬂora, oral cavity,
upper respiratory tract and intestinal tract [1–3].
P. acnes is associated with the inﬂammatory pro-
cesses in acne lesions, and resistance of P. acnes to
antimicrobial agents has often been encountered in
acne patients in response to oral and topical
antibiotic therapy [4]. It has also been found that
antibiotic therapy determines the emergence of
antimicrobial resistance in close contacts of such
patients [5].
During recent years, the prevalence of life-
threatening infections caused by P. acnes has
increased [6]. These infections generally occur in
compromised patients, in newborn infants [7] and,
less frequently, in previously healthy individuals
[8]. According to Brook and Frazier [9], predispo-
sing conditions include: the presence of foreign
bodies, diabetes, previous surgery, trauma, malig-
nancy, immunodeﬁciency and steroid therapy.
Systemic infections are associated more frequently
with surgical procedures, such as cerebrospinal
ﬂuid shunts or the implantation of prosthetic
devices (heart valves, orthopaedic implants, intra-
ocular lenses) [10,11]. It is possible for these
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infections to appear either shortly after surgery
(as a result of a high inoculum) or after a longer
period. The second possibility is explained by the
fact that P. acnes resides intracellularly and can
remain in a dormant state for months or years
[6,12]. The management of severe infections
should involve a combination of parenteral anti-
microbial agents and surgical procedures (e.g.,
removal of the device or drainage of the infected
site) [6,9]. Benzylpenicillin is the drug of choice for
serious infections, with clindamycin, tetracycline,
erythromycin, chloramphenicol and vancomycin
as alternatives in cases of allergy or concern about
resistance to b-lactam agents [13]. All isolates
collected from serious infections should be tested
for in-vitro susceptibility, because of the possible
recovery of resistant strains [13,14].
The ﬁrst objective of the present study was to
evaluate the activity of six antimicrobial agents
against clinical isolates of P. acnes from 13 Euro-
pean countries. The second objective was to
determine the genomic diversity and the epide-
miological relatedness among resistant P. acnes
isolates by using pulsed-ﬁeld gel electrophoresis
(PFGE).
MATERIALS AND METHODS
Bacterial isolates
Laboratories in each country included in the study (Croatia,
Czech Republic, Denmark, Finland, Germany, Greece, Hun-
gary, Italy, The Netherlands, Norway, Slovenia, Sweden and
Great Britain) collected consecutive, non-duplicate isolates of
P. acnes, together with information regarding sampling day,
type of infection and antibiotic treatment. The isolates were
sent to the Division of Clinical Bacteriology, Karolinska
University Hospital Huddinge, Karolinska Institute, Stock-
holm, Sweden. The study was approved by the Ethics
Committee of the hospital. The strains were identiﬁed by
Gram’s stain, biochemical tests (Rapid-Ana II System; REMEL
Inc., Lenexa, KS, USA) [15] and gas chromatography. Follow-
ing identiﬁcation, the isolates were frozen () 70C) until
required; susceptibility testing was performed simultaneously
with all isolates.
Determination of MICs
MICs of six antimicrobial agents were determined by the
NCCLS agar dilution technique, with 105 CFU ⁄ spot and
brucella base sheep blood agar [16]. The plates were incubated
in anaerobic jars (GasPakAnaerobic System; BBL, Cockeysville,
MD, USA) for 48 h at 37C. The MIC was deﬁned as the lowest
concentration of antimicrobial agent that resulted in a marked
change in the appearance of growth in comparison with the
control plate, as described in the NCCLS protocol. P. acnes
ATCC 6919, P. acnes ATCC 11828, Bacteroides fragilis ATCC
25285, Bacteroides thetaiotaomicronATCC 29741 and Enterococcus
faecalis ATCC 29212 were used as control strains. Tetracycline
was obtained from Wyeth Ayerst (Pearl River, NY, USA),
clindamycin from Pharmacia Upjohn (Kalamazoo, MI, USA),
erythromycin and benzylpenicillin from AstraZeneca (So¨der-
ta¨lje, Sweden), linezolid from Pharmacia Upjohn (Milan, Italy),
and vancomycin from Abbott Scandinavia (Solna, Sweden).
Genotypic analysis with PFGE
Genomic DNA was prepared in agarose plugs, digested with
SpeI restriction endonuclease (Promega, Madison, WI, USA)
and electrophoresed using a contour-clamped homogeneous
electric ﬁeld apparatus (Gene Path System; Bio-Rad Laborat-
ories, Hercules, CA, USA) as described previously [17]. All
antibiotic-resistant isolates (n = 89) and two P. acnes reference
strains (ATCC 6919 andATCC 11828) were typed by PFGE [18].
Computerised numerical analysis of PFGE data
Calculation of similarity matrices and creation of dendrograms
were done with the Molecular Analyst Software program
(Bio-Rad), using the unweighted pair-group method with
arithmetic averages (UPGMA). The similarity coefﬁcients were
calculated according to the method of Dice [19]. P. acnes ATCC
6919 was used as a control for each gel experiment to allow
comparisons within the Molecular Analyst Software program.
The clonal group level was set at ‡ 80% similarity. Capital
letters (A–Q) were used to designate the main genetic lineages
observed [17]. The preparation and digestion of DNA from
isolates chosen randomly were repeated under the same
conditions to assess the reproducibility of the method.
Analysis of results
For comparison of results from different regions of Europe, the
countries were grouped as follows: north—Denmark, Finland,
Norway and Sweden; south—Greece and Italy; east—Croatia,
Czech Republic, Hungary and Slovenia; and west—Germany,
Great Britain and The Netherlands.
The results were registered in a single database, and
analysed and validated with WHONET 5 (World Health
Organization, Geneva, Switzerland) and Statistica v. 6.0 soft-
ware (StatSoft, Tulsa, OK, USA).
Susceptibility breakpoints used were those recommended
by the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) guidelines [17,20] (tetracycline,
MIC ‡ 2 mg ⁄L; clindamycin, MIC ‡ 0.25 mg ⁄L; erythromycin,
MIC ‡ 0.5 mg ⁄L; linezolid, MIC ‡ 8 mg ⁄L; benzylpenicillin,
MIC ‡ 0.25 mg ⁄L; and vancomycin, MIC ‡ 4 mg ⁄L).
The correlations between antibiotic resistance rates and the
reported sales of antibiotics in eight European countries were
analysed with a linear regression model, with a value of
p < 0.05 set as the level of signiﬁcance.
RESULTS
Distribution and source of P. acnes isolates
Each participating country was originally sup-
posed to contribute a maximum of 50 isolates to
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the study, but some participants had difﬁculty in
collecting the agreed number of isolates (Table 1).
In total, 328 clinical isolates collected between
1996 and 2002 were received, but 24 isolates not
belonging to P. acnes were excluded from the
study. The distribution of isolates according to the
country and type of infection is shown in Table 1.
Most (18.7%) isolates were received from Italy,
and blood isolates (n = 105), followed by those
from skin and soft tissue infections (n = 77), were
encountered most frequently.
Antimicrobial susceptibilities
MIC values are shown in Table 2. The MICs for
the control strains were always within recom-
mended limits.
Clindamycin
Of the clinical isolates, 15% were resistant to
clindamycin. Most resistant isolates were associ-
ated with meningitis (21.4%), prosthetic devices
(20%) and blood (20%).
Erythromycin
Resistance to erythromycin was shown by 17% of
the isolates. MICs ranged between < 0.064 and
> 128 mg ⁄L. Most resistant isolates were asso-
ciated with blood (31.4%), meningitis (21.4%),
abdominal infections (18.2%) and lung and
pleural ﬂuids (16.7%).
Tetracycline
Most P. acnes isolates were susceptible to tetra-
cycline, with both the MIC50 and MIC90 values
below the breakpoint for tetracycline, and < 3% of
all isolates showing resistance. Tetracycline-resis-
tant isolates were associated with biliary, bone,
head and neck, skin ⁄ soft tissue and blood infec-
tions.
Linezolid
Linezolid was active against all P. acnes isolates,
with MICs between 0.25 and 2 mg ⁄L.
Benzylpenicillin
All the clinical isolates were uniformly suscept-
ible to low concentrations of penicillin, with MICs
between 0.008 and 0.125 mg ⁄L.
Vancomycin
All the isolates were susceptible to vancomycin.
Resistance proﬁles
Overall, 29% of P. acnes isolates were resistant to
at least one of the tested antimicrobial agents.
Most (83%) of these isolates were resistant to only
one antibiotic, and most of the erythromycin-
resistant or clindamycin-resistant isolates were
from Italy (Table 3).
The MICs of erythromycin and clindamycin
for isolates resistant to both antimicrobial
agents, as well as the MICs for isolates resistant
to each of these antimicrobial agents indivi-
dually, are presented in Fig. 1. In the case
of double-resistance (clindamycin and erythro-
mycin), the MICs were higher for most iso-
lates than for isolates with single antibiotic
resistance.
Table 1. Distribution and source of
isolates of Propionibacterium acnes
Source of isolate (no.)
Country (no. of isolates)
DNK FIN NOR SWE GRE ITA CRO CZE HUN SVN GER GBR NLD
Blood (105) 18 3 7 38 5 16 11 3 3 1
Skin ⁄ soft tissue (77) 8 9 4 35 11 8 1 1
Abdominal infection (22) 1 1 3 5 6 2 1 3
Head ⁄neck (19) 13 2 1 3
Bone (15) 11 4
Meningitis (14) 6 1 3 3 1
Eye infection (13) 3 3 2 5
Endocarditis (13) 1 3 4 5
Prosthetic device (10) 6 3 1
Lung ⁄pleural ﬂuid (6) 2 2 2
Bile (4) 3 1
Lymph node (2) 2
Female genital tract (2) 2
Arthritis (1) 1
Faeces (1) 1
Total (304) 18 17 8 26 9 57 6 43 41 31 11 30 7
% 5.9 5.5 2.6 8.5 2.9 18.7 1.9 14.1 13.4 10.1 3.6 9.8 2.3
DNK, Denmark; FIN, Finland; NOR, Norway; SWE, Sweden; GRE, Greece; ITA, Italy; CRO, Croatia; CZE, Czech
Republic; HUN, Hungary; SVN, Slovenia; GER, Germany; GBR, Great Britain; NLD, the Netherlands.
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Prevalence of resistant bacteria from different
countries
There was considerable variation between coun-
tries in the proportion of resistant isolates,
ranging from 83% in Croatia and 60% in Italy,
to 7% in Great Britain and 0% in The Nether-
lands. All resistant isolates collected from
Denmark, Croatia and Norway, and also many
of the resistant isolates from Italy, Slovenia and
Hungary, were obtained from blood (Table 4).
The clindamycin MIC90 value was highest for
Greek isolates (32 mg ⁄L), while the highest values
for erythromycin were found in isolates from
Greece, Croatia and Slovenia (‡ 128 mg ⁄L). One
isolate from Norway had the highest tetracycline
MIC (8 mg ⁄L) (Table 5).
Antibiotic resistant rates from different
countries/regions
The highest prevalence of resistance was detected
in isolates from the southern European regions
(Greece and Italy), where 54.5% of isolates were
resistant. The lowest prevalence (6.2%) was found
in the western European countries (Germany,
Great Britain and The Netherlands). In the eastern
regions (Croatia, Czech Republic, Hungary and
Slovenia), the situation did not differ from the rest
of Europe, although there was considerable vari-
ation from country to country (Table 6).
Some correlations (Table 6) were noted when
the results from this study were compared with
published data [21] on outpatient antibiotic sales
in countries of the European Union. In Finland,
the country with the highest use of tetracycline, a
higher rate (11.8%) of tetracycline resistance
among P. acnes isolates was found. In Italy,
currently with the lowest tetracycline consump-
tion, no isolates were tetracycline-resistant. Sim-
ilar correlations were observed between the
highest sales of macrolides and lincosamides
(MLS) in Italy and high rates of resistance to
erythromycin (42.1%) and clindamycin (21.1%).
Sweden has reported a large reduction in antibi-
otic use, but the rates of resistance to clindamycin
and erythromycin were 11.5% for both antimi-
crobial agents. The very low rate of non-hospital
antibiotic use in The Netherlands (Table 6) was
reﬂected in the present results by the absence of
resistant isolates.
The antibiotic resistance rates were found to
correlate with the sale of MLS agents for the eight
countries from the European Union that reported
these data (Table 6) for clindamycin (p < 0.05,
r = 0.753; Fig. 2a) and erythromycin (p < 0.05,
r = 0.713; Fig. 2b). No correlation was found
between tetracycline-resistant rates and the sale
of tetracycline in these countries.
PFGE typing
All resistant isolates were distinguishable by
PFGE. Seventy-eight different patterns of SpeI
DNA digests were detected. Among the 91
isolates studied, a band-based cluster analysis
revealed 17 clones (A–Q) with a cut-off value of
80% similarity. Visual analysis revealed that
isolates from the same clone had fewer than
three bands different, while the number of band
differences between isolates belonging to differ-
ent clones was greater than four. Each clone
included between one and 32 isolates. The largest
cluster of isolates (n = 32; 35.1%) was grouped
into clone F. Ten clones comprised single isolates
(Table 7).
Table 3. Resistance proﬁles of 304 clinical isolates of
Propionibacterium acnes from 13 European countries
Proﬁle
No. of
isolates (%) Country (no. of isolates)
Susceptible 215 (70.7)
Resistant 89 (29.2)
TCY 5 (5.6) CZE (3); FIN (2)
EM 37 (41.5) ITA (22); SVN (6); DNK (4); SWE (2);
CZE, CRO, GBR(1)
CL 32 (35.9) ITA (10); SVN (7); HUN (6); CZE, SWE (3);
CRO, DNK, GBR (1)
EM; TCY 1 (1.1) SWE (1)
CL; EM 12 (13.4) SVN (5); CRO (3); ITA (2); GER (1); GRE (1)
CL; EM; TCY 2 (2.2) NOR (1); GRE (1)
CL, clindamycin; EM, erythromycin; TCY, tetracycline; DNK, Denmark; FIN,
Finland; NOR, Norway; SWE, Sweden; GER, Germany; GBR, Great Britain; NLD,
The Netherlands; GRE, Greece; ITA, Italy; CRO, Croatia; CZE, Czech Republic;
HUN, Hungary; SVN, Slovenia.
Table 2. In-vitro activity of six antimicrobial agents
against 304 isolates of Propionibacterium acnes
Antibiotic
Breakpoint
(mg ⁄L)a
MIC (mg ⁄L) Resistant
isolates
(%)MIC50 MIC90 Range
Clindamycin 0.25 < 0.064 0.25 < 0.064–64 15.1
Erythromycin 0.5 0.25 0.5 < 0.064 to > 128 17.1
Tetracycline 2 0.5 1 < 0.064–32 2.6
Linezolid 8 0.5 1 0.25–2 0
Benzylpenicillin 0.25 0.032 0.064 0.008–0.125 0
Vancomycin 4 0.5 1 0.25–2 0
aBreakpoints recommended by the European Committee on Antibiotic Susceptibil-
ity Testing (EUCAST) [17,20].
Oprica and Nord Antibiotic susceptibility of P. acnes 207
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 204–213
Country distribution of different PFGE clones
Clonal type F was composed of isolates from ten
different countries (Table 7). Clone H was
composed mainly of isolates from Italy. Some
P. acnes clones (A, B, G, H) were spread over
distant areas, but other clones comprised isolates
from neighbouring countries only (clones D and I
were found only in Italy and Slovenia). Some
isolates from the same country (Denmark, Italy
and Slovenia) or from the same geographical area
(Croatia and Italy), but also isolates from very
different regions (Denmark and Slovenia),
showed 100% similarity. In contrast, some iso-
lates from Denmark, Italy, Czech Republic, Slo-
venia, Sweden and Great Britain were unlinked to
any other clones (Table 7). There was no relation-
ship between the distribution of clones and the
infection type (Table 8), but 38% of resistant
isolates from blood and 60% of those from soft
tissue infections belonged to clone F.
PFGE and resistance phenotype
Clone F contained 69% of the clindamycin-
resistant isolates, with MICs of 0.25–1 mg ⁄L,
while isolates with other PFGE patterns had
Table 4. Resistant isolates of Propionibacterium acnes from
13 European countries and their clinical sources
Country
(no. of isolates)
No. of resistant
(% resistant) Source of isolation (no. of isolates)
DNK (18) 5 (28%) Blood (5)
FIN (17) 2 (12%) Head ⁄neck, faeces (1)
NOR (8) 1 (13%) Blood (1)
SWE (26) 6 (23%) Bone, soft tissue (2);
abdominal abscess, skin (1)
GER (11) 1 (9%) Soft tissue (1)
GBR (30) 2 (7%) Meningitis, head ⁄neck (1)
NLD (7) – –
GRE (9) 2 (22%) Skin (2)
ITA (57) 34 (60%) Blood (23); meningitis,
abdominal abscess, soft tissue (3);
eye, pleuresia (1)
CRO (6) 5 (83%) Blood (5)
CZE (43) 7 (16%) Skin (4); soft tissue (2); bile (1)
HUN (41) 6 (15%) Blood (3); abdominal infection (2); skin (1)
SVN (31) 18 (58%) Blood (8); meningitis,
abdominal abscess, soft tissue,
prosthetic device (2); eye, head ⁄neck (1)
DNK, Denmark; FIN, Finland; NOR, Norway; SWE, Sweden; GRE, Greece; ITA,
Italy; CRO, Croatia; CZE, Czech Republic; HUN, Hungary; SVN, Slovenia; GER,
Germany; GBR, Great Britain; NLD, the Netherlands.
Fig. 1. (a) Clindamycin MICs for the isolates resistant to both clindamycin and erythromycin; MIC range = 0.25–64 mg ⁄L,
73% of strains have MIC ‡ 2 mg ⁄L. (b) Erythromycin MICs for the isolates resistant to both clindamycin and
erythromycin; MIC range = 0.5–128 mg ⁄L, 84% of strains have MIC ‡ 2 mg ⁄L. (c) Clindamycin MICs for the
clindamycin-resistant isolates; MIC range = 0.25–2 mg ⁄L, 3% of strains have MIC ‡ 2 mg ⁄L. (d) Erythromycin MICs
for the erythromycin-resistant isolates; MIC range = 0.5–128 mg ⁄L, 11% of strains have MIC ‡ 2 mg ⁄L.
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clindamycin MICs of < 0.064–2 mg ⁄L (Fig. 3).
Clone H contained 46% of the erythromycin-
resistant isolates, with MICs of 0.5–1 mg ⁄L, while
other erythromycin-resistant isolates had MICs of
0.5–128 mg ⁄L.
DISCUSSION
P. acnes, which is considered to be a microorgan-
ism with low virulence, has an important role in
acne. There is not always a correlation between
Propionibacterium levels and the severity of acne
[22], but it is well known that P. acnes triggers
inﬂammatory reactions in this common skin
disease. Generally, however, propionibacteria
have a poorly deﬁned role in severe infections.
Even when the bacterium was cultured, it was
considered to be a contaminant, especially if
isolated following percutaneous punctures or
biopsies [6,12]. However, a positive culture for
P. acnes cannot be dismissed as a contaminant
without considering the clinical circumstances.
Thus, although P. acnes originates from the nor-
mal ﬂora, it can act as a primary pathogen [6,9,13].
Susceptibility testing of anaerobic bacteria does
not normally inﬂuence therapeutic decisions,
because of the slow growth of the bacteria, the
cost and complexity of testing methods, and a
Table 5. In-vitro activities of six
antimicrobial agents against Propion-
ibacterium acnes isolates from differ-
ent European countries
Country
(no. of isolates ⁄
no. of resistant
isolates)
MIC50 ⁄MIC90 (mg ⁄L)
CL
(‡ 0.25)a
EM
(‡ 0.5)a
TCY
(‡ 2)a
LNZ
(‡ 8)a
PEN
(‡ 0.25)a
VAN
(‡ 4)a
DNK (18 ⁄ 5) < 0.064 ⁄ 0.125 0.125 ⁄ 0.5 0.5 ⁄ 1 0.5 ⁄ 1 0.016 ⁄ 0.064 1 ⁄ 1
FIN (17 ⁄ 2) < 0.064 ⁄< 0.064 0.25 ⁄ 0.25 1 ⁄ 2 1 ⁄ 1 0.032 ⁄ 0.064 1 ⁄ 1
NOR (8 ⁄ 1) < 0.064 ⁄ 2 0.125 ⁄ 8 1 ⁄ 8 0.5 ⁄ 2 0.016 ⁄ 0.064 1 ⁄ 1
SWE (26 ⁄ 6) < 0.064 ⁄ 0.25 0.125 ⁄ 64 0.5 ⁄ 1 0.5 ⁄ 1 0.032 ⁄ 0.125 1 ⁄ 1
GER (11 ⁄ 1) < 0.064 ⁄< 0.064 0.25 ⁄ 0.25 1 ⁄ 1 0.5 ⁄ 0.5 0.016 ⁄ 0.032 1 ⁄ 1
GBR (30 ⁄ 2) < 0.064 ⁄ 0.125 0.25 ⁄ 0.25 0.5 ⁄ 1 1 ⁄ 1 0.032 ⁄ 0.064 0.5 ⁄ 0.5
NLD (7 ⁄ 0) < 0.064 ⁄< 0.064 0.25 ⁄ 0.25 1 ⁄ 1 0.5 ⁄ 0.5 0.016 ⁄ 0.064 0.5 ⁄ 1
GRE (9 ⁄ 2) < 0.064 ⁄ 32 0.25 ⁄> 128 1 ⁄ 4 0.5 ⁄ 0.5 0.032 ⁄ 0.125 0.5 ⁄ 0.5
ITA (57 ⁄ 34) < 0.064 ⁄ 0.5 0.25 ⁄ 0.5 0.5 ⁄ 1 0.5 ⁄ 0.5 0.064 ⁄ 0.125 0.5 ⁄ 1
CRO (6 ⁄ 5) 0.25 ⁄ 2 0.5 ⁄> 128 1 ⁄ 1 0.5 ⁄ 0.5 0.016 ⁄ 0.032 1 ⁄ 1
CZE (43 ⁄ 7) < 0.064 ⁄< 0.064 0.25 ⁄ 0.25 0.5 ⁄ 1 1 ⁄ 1 0.016 ⁄ 0.064 0.5 ⁄ 1
HUN (41 ⁄ 6) < 0.064 ⁄ 0.25 < 0.064 ⁄ 0.25 0.25 ⁄ 0.5 0.5 ⁄ 1 0.016 ⁄ 0.032 0.5 ⁄ 1
SVN (31 ⁄ 18) 0.125 ⁄ 4 0.25 ⁄ 128 1 ⁄ 1 0.5 ⁄ 1 0.016 ⁄ 0.064 1 ⁄ 1
CL, clindamycin; EM, erythromycin; TCY, tetracycline; LNZ, linezolid; PEN, penicillin; VAN, vancomycin; DNK,
Denmark; FIN, Finland; NOR, Norway; SWE, Sweden; GRE, Greece; ITA, Italy; CRO, Croatia; CZE, Czech Republic;
HUN, Hungary; SVN, Slovenia; GER, Germany; GBR, Great Britain; NLD, the Netherlands.
aBreakpoint recommended by the European Committee on Antibiotic Susceptibility Testing (EUCAST) [17,20].
Table 6. Antibiotic resistance rates
among Propionibacterium acnes iso-
lates from different countries ⁄
regions of Europe and comparison
with reported non-hospital antibi-
otic sales in European Union coun-
tries (data available for only eight of
the countries participating in the
study); the countries were divided
into four main geographical regions
Region/country
(no. of isolates/
no. of resistant
isolates)
% of isolates resistant to antibiotic
% Resistant
isolates
Antibiotic salesa
CL
‡ 0.25b
EM
‡ 0.5b
TCY
‡ 2b
LNZ
‡ 8b
PEN
‡ 0.25b
VAN
‡ 4b
Macrolides ⁄
lincosamides Tetracycline
North (69 ⁄ 14) 7.2 11.6 5.8 0 0 0 20.2
DNK (18 ⁄ 5) 5.6 22.2 0 0 0 0 1.97 0.98
FIN (17 ⁄ 2) 0 0 11.8 0 0 0 1.86 5.50c
NOR (8 ⁄ 1) 12.5 12.5 12.5 0 0 0
SWE (26 ⁄ 6) 11.5 11.5 3.8 0 0 0 0.97d 2.97
West (48 ⁄ 3) 4.2 4.2 0 0 0 0 6.2
GER (11 ⁄ 1) 9.1 9.1 0 0 0 0 2.54 3.26
GBR (30 ⁄ 2) 3.3 3.3 0 0 0 0 3.22 3.66
NLD (7 ⁄ 0) 0 0 0 0 0 0 1.24 2.35
South (66 ⁄ 36) 21.2 39.4 1.5 0 0 0 54.5
GRE (9 ⁄ 2) 22.2 22.2 11.1 0 0 0 4.5 2.69
ITA (57 ⁄ 34) 21.1 42.1 0 0 0 0 5.07c 0.56d
East (121 ⁄ 36) 20.7 13.2 2.5 0 0 0 29.7
CRO (6 ⁄ 5) 66.7 66.7 0 0 0 0
CZE (43 ⁄ 7) 7 2.3 7 0 0 0
HUN (41 ⁄ 6) 14.6 0 0 0 0 0
SVN (31 ⁄ 18) 38.7 35.5 0 0 0 0
CL, clindamycin; EM, erythromycin; TCY, tetracycline; LNZ, linezolid; PEN, benzylpenicillin; VAN, vancomycin;
DNK, Denmark; FIN, Finland; NOR, Norway; SWE, Sweden; GRE, Greece; ITA, Italy; CRO, Croatia; CZE, Czech
Republic; HUN, Hungary; SVN, Slovenia; GER, Germany; GBR, Great Britain; NLD, The Netherlands.
aDaily dose ⁄ 1000 inhabitants ⁄day.
bBreakpoints.
cHighest deﬁned daily dose (data available from eight countries).
dLowest deﬁned daily dose (data available from eight countries).
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general opinion that susceptibility patterns
among anaerobes are predictable [23]. In the
present study, different selection pressures
appeared to operate for each country or region,
but the highest rates of resistant isolates were
found in southern European countries and the
lowest rates in western European areas (Table 6).
Surprisingly, despite a very restrictive policy
regarding antibiotic prescription, the overall
resistance rate for Swedish P. acnes isolates was
higher than for other northern and western
European countries.
Many isolates were resistant to clindamycin
and ⁄ or erythromycin (Table 3), and these were
isolated principally from severe infections. In
some countries (Italy and Greece) there was a
correlation with sales of antibiotics, but this was
not observed for Sweden and Denmark (Table 6).
It is possible that topical clindamycin, used
commonly for the treatment of acne, could
account for the correlation, but it is unlikely that
all patients carrying resistant isolates were acne
patients or had contact with acne patients. Great
Britain has a high consumption rate of macro-
lides ⁄ lincosamides, but the resistance rates were
still lower than in Italy or Greece. Overall, a
higher prevalence of erythromycin resistance was
observed in southern Europe, and a higher
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Fig. 2. Correlation between the reported sales of macrolides ⁄ lincosamides (MLS) in eight EU countries and the resistance
rates to (a) clindamycin, and (b) erythromycin in these countries. By linear regression analysis, the clindamycin and
erythromycin resistance rates correlate with the reported sales of MLS (1.4998 + 0.12846 · clindamycin resistance rates,
p < 0.05, r = 0.753; and 1.6551 + 0.07345 · erythromycin resistance rates, p < 0.05, r = 0.713, respectively). Solid lines show
mean values; dashed lines show 95% conﬁdence intervals.
Table 7. Country of origin of 89 resistant Propionibacterium
acnes isolates and their assignment by pulsed-ﬁeld gel
electrophoresis to individual clones (two reference strains,
ATCC 6919 and ATCC 11828, were included in the
analysis)
Clonal type
(no. of resistant isolates) Country (no. of isolates)
A (9) ITA (6), SVN, SWE (1); ATCC 11828
B (5) ITA (3); CZE, FIN (1)
C (1) DEN (1)
D (2) ITA, SVN (1)
E (1) ITA (1)
F (32) ITA (9), SVN (7), HUN (5), CRO (4), SWE (2);
CZE, DEN, FIN, GBR, NOR (1)
G (11) CZE, GRE, ITA (2); GER, HUN, SVN, SWE (1);
ATCC 6919
H (20) ITA (11); SVN (5); DEN (3); CRO (1)
I (2) ITA, SVN (1)
J (1) CZE (1)
K (1) CZE (1)
L (1) SVN (1)
M (1) SVN (1)
N (1) GBR (1)
O (1) CZE (1)
P (1) SWE (1)
Q (1) SWE (1)
DNK, Denmark; FIN, Finland; NOR, Norway; SWE, Sweden; GRE, Greece; ITA,
Italy; CRO, Croatia; CZE, Czech Republic; HUN, Hungary; SVN, Slovenia; GER,
Germany; GBR, Great Britain; NLD, The Netherlands.
Table 8. Types of infection from which 89 resistant
Propionibacterium acnes isolates were obtained
Type of infection
(no. of resistant strains) Clonal type (no. of strains)
Blood (45) C, E, M (1); B, D, I, G (2); A (3); F (17); H (14)
Soft tissue (10) O, P (1); G (2); F (6)
Skin (8) B, J, K (1); F (2); G (3)
Abdominal abscess (7) G (1); A, F, H (2)
Meningitis (6) A, B, F, L (1); H (2)
Eye (2) F (2)
Head ⁄neck (3) B, H, N (1)
Prosthetic device (2) F, H (1)
Pleuresia (2) A, G (1)
Bone (2) A, Q (1)
Biliary infection (1) G (1)
Faeces (1) F (1)
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prevalence of clindamycin resistance in southern
and eastern Europe (Table 6).
Tetracycline resistance was encountered less
frequently than clindamycin and erythromycin
resistance, and most of the tetracycline-resistant
isolates were from northern European countries,
whereas no tetracycline-resistant isolates were
identiﬁed in western European countries.
Although tetracycline is still used for a variety
of diseases, fewer resistant isolates were found
than for other antimicrobial agents, as has also
been shown for skin samples from acne patients
[17,24]. In comparison to other countries from the
same region, lower resistance rates were found
for isolates from Hungary and the Czech Republic
(Table 6). These results are in agreement with
those of other recent studies investigating skin
samples [24].
Linezolid belongs to a new class of antimicro-
bial agents, the oxazolidinones, and is considered
to be active against Gram-positive aerobic and
anaerobic bacteria [11,25]. However, Auckland
et al. [26] described the isolation of linezolid-
resistant enterococci from patients who had
received this antibiotic. The present study did
not detect any resistance to linezolid among the
P. acnes isolates tested, but clinicians should be
aware of the risk that P. acnes isolates may become
resistant to this antibiotic in the future.
As demonstrated in the present study, there is a
potential risk of life-threatening infections, e.g.,
septicaemia or meningitis, with antibiotic-resist-
ant P. acnes. Fortunately, this bacterium is usually
susceptible to b-lactams, such as penicillin or
vancomycin, that are used to treat serious
infections, and shows resistance mainly to eryth-
romycin, clindamycin and tetracycline [17,27,28].
Acne patients are usually treated with many oral
and topical antimicrobial agents, and their normal
ﬂora is exposed to a great selective pressure for
resistance development. Although resistance in
P. acnes seems to result mainly from a mutational
event in the 23S rRNA ribosomal binding site for
MLS antimicrobial agents or the 16S rRNA ribo-
somal binding site for tetracycline [29,30], it has
been reported that a corynebacterial transposon,
Tn5432, which carries the rRNA methylase erm
(X) (erythromycin ribosome methylase) gene, can
determine resistance to MLS agents [31]. It is not
impossible that other mobile resistance genes
coming from different species may be transferable
to skin propionibacteria [31], and this could lead
subsequently to acute infections caused by resist-
ant P. acnes isolates.
PFGE is a robust typing method that can
establish strain relatedness among bacteria with
the same multiple antibiotic resistance pattern,
and can determine whether a particular clone is
more prone to become resistant. Criteria estab-
lished by Tenover et al. [32] are applicable for
small sets of epidemiologically related isolates
(£ 30) and for investigating outbreaks. The pre-
sent study investigated a large number of iso-
lates, collected over a 6-year period from a wide
area, and these inclusion criteria were not con-
sidered appropriate for determining the genomic
diversity among the isolates. PFGE has been used
previously for epidemiological studies involving
P. acnes [17]. Thus, relative homogeneity among
69 resistant isolates from the skin of acne patients
in a single geographical area has been reported
[17], but until the present study, there were no
data regarding the genetic diversity of resistant
P. acnes clinical isolates from Europe. Perry et al.
[33] used random ampliﬁcation of polymorphic
DNA for typing clinical isolates of P. acnes, and
reported that two isolates of different serotypes
belonged to two different clones. In the present
study, P. acnesATCC 6919 (serotype I) and P. acnes
ATCC 11828 (serotype II) were also found to
belong to different clones, with less than 60%
similarity. In the future, PFGE could be used to
distinguish between different P. acnes serotypes.
The present study showed a high level of genomic
diversity, reﬂected by the large number of differ-
ent PFGE patterns and the presence of isolates
that did not cluster with other clones.
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Fig. 3. Distribution of six resistant phenotypes among 17
clones identiﬁed by pulsed-ﬁeld gel electrophoresis. CL,
clindamycin; EM, erythromycin; TCY, tetracycline.
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It is important to note that some clones appear
to have spread not only in related areas, but also
in more distant countries (Table 7). Isolates
belonging to the same clone from neighbouring
countries may have similar or different patterns of
antibiotic resistance. The ﬁrst example may rep-
resent the spread of the same clone in geograph-
ically closed regions, while in the second case the
clone may be formed of isolates that are more
prone to become resistant to different antimicro-
bial agents. P. acnes isolates from different types
of infection were distributed among different
clones, but a correlation was observed between
isolates with low-level resistance to erythromycin
or clindamycin and certain clonal types. It was
therefore concluded that most clindamycin-resist-
ant or erythromycin-resistant P. acnes isolates are
members of a single clone that has spread in
different areas in Europe. Similar ﬁndings regard-
ing the clonal distribution of clindamycin-resist-
ant isolates were obtained in a recent study in
which skin samples from acne patients were
characterised [17].
The international variations in resistance rates,
even within Europe, highlight the importance of
the selective pressure exerted by inappropriately
used antimicrobial agents. However, sales data
cannot be equated with antibiotic exposure with-
out consideration of the problem of patient
compliance, which is very difﬁcult to measure.
Low compliance and self-medication may con-
tribute to resistance [34]. It is known that the level
of antimicrobial resistance can differ from one city
to another, and even within the same city,
differences can exist between hospitals. The data
presented here are representative for each country
and geographical region, which could be a limi-
tation of the study. However, epidemiological
studies can provide useful information, which can
be used to stimulate discussion concerning
regional differences in prevalence rates and
help in the development of strategies to combat
the rising problem of antibiotic resistance in
P. acnes.
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